Lunai Bioworks (LNAI) Q3 2026 earnings summary

Executive summary

• Focused on AI-driven precision medicine, diagnostics, and biodefense, with two main subsidiaries: Renovaro Biosciences (cell/gene therapy) and BioSymetrics (AI platform for biomarker discovery and therapeutic development).

• Acquired BioSymetrics in April 2025 and deconsolidated GediCube B.V. after its bankruptcy in September 2025, recognizing a $12M gain.

• Streamlined operations and reduced overhead to focus on core AI neurology and oncology platforms.

Financial highlights

• Service revenue of $20,942 for both the three and nine months ended March 31, 2026, from a single research services contract; no revenue in prior periods.

• Net loss of $2.57M for the quarter, compared to net income of $189K in the prior year; net loss of $1.55M for the nine months, a significant improvement from $51.3M loss in the prior year.

• Operating expenses decreased 65% year-over-year for the quarter and 89% for the nine months, mainly due to lower G&A, R&D, and absence of goodwill impairment.

• Cash balance of $3.16M as of March 31, 2026, up from $92.7K at June 30, 2025; working capital deficit improved to $15.6M from $28.1M.

Outlook and guidance

• Management expects to require additional funding through equity or debt to continue operations and support commercialization and development activities.

• Substantial doubt exists about the ability to continue as a going concern for one year after the financial statements are issued.

• Funding received in 2026 will be used for obligations, working capital, commercialization, and clinical/regulatory work.